CARMEL, Ind., March 12, 2026 (GLOBE NEWSWIRE) -- NeurAxis, Inc. (“NeurAxis,” or the “Company”) (NYSE American: NRXS), a medical technology company commercializing neuromodulation therapies addressing ...
NeurAxis reports 43% revenue growth in Q4 2024, significant advancements in insurance coverage, and FDA approvals for its technologies. NeurAxis, Inc. reported its fourth quarter and fiscal year 2024 ...
NeurAxis, Inc. will announce its financial results for the fourth quarter and fiscal year 2024, which ended on December 31, 2024, on March 20, 2025, prior to the market opening. A conference call to ...
CARMEL, Ind., May 05, 2026 (GLOBE NEWSWIRE) -- NeurAxis, Inc. (“NeurAxis,” or the “Company”) (NYSE American: NRXS), a medical technology company commercializing neuromodulation therapies addressing ...
CARMEL, Ind., March 12, 2026 (GLOBE NEWSWIRE) -- NeurAxis, Inc. (NRXS), a medical technology company commercializing neuromodulation therapies addressing chronic and debilitating conditions in ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results